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control group included 25 propensity score matched clients
(95,054 lives) not enrolled in the program. In the study group,
the average total cost per prescription (normalized to 90-day
supply) was signiﬁcantly lower in 90-day retail than in mail
service and 30-day retail ($165.9 vs. $170.65 vs. $185.9). The
generic utilization rate in 90-day retail was higher than in mail
service but lower than 30-day retail (38.36% vs. 37.38% vs.
39.75%). From the pre to post period, in study group, PMPM
total, plan and member costs among eligible lives increased by
7% (from $29.54 to $31.60), 6.5% (from $22.29 to $23.73) and
7.3% (from $7.11 to $7.63). In the control group, PMPM total,
plan and member increased by 10.1% (from $30.16 to $33.22),
10.4% (from $22.33 to $24.65) and 9.3% (from $7.72 to
$8.43). It was estimated that this 90-day retail program had
PMPM cost savings of $0.89, $0.79 and $0.10 for the total, plan
and members. CONCLUSIONS: A 90-day retail program was
found to have decreased total, health plan and member pre-
scription drug costs.
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EXPENDITURES UNDER THE NEW MEDICARE DRUG LAW
FOR PATIENTS WITH MENTAL DISORDERS—AN ANALYSIS OF
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OBJECTIVES: Estimate out-of-pocket pharmacy expenditures
for elderly retirees with employer-sponsored coverage, under the
standard Medicare drug plans that began on January 1, 2006.
METHODS: Data came from the Medstat MarketScan Medicare
Database, for 2004. Data included all medical and pharmacy
claims for 1,220,902 seniors enrolled in retiree plans offered by
large employers. (About 30% of non-institutionalized Medicare
enrollees have retiree coverage.) Payments covered by the
Medicare program and by private insurance were included.
Analyses focused on 30,681 patients with diagnoses of depres-
sion, anxiety disorder, or schizophrenia in 2004. We estimated
the out-of-pocket payments that would have been incurred by
these beneﬁciaries, if the Medicare drug law had been in effect
during 2004. We also estimated how long it may take to enter
the “donut hole” where coverage stops (i.e., that period during
which total pharmacy expenditures range from $2251 to $5100).
RESULTS: Mean total pharmacy payments for these mental
health patients were higher than payments for other patients
with retiree coverage ($4491 for depression patients, $3364 for
anxiety patients, and $5321 for schizophrenia patients, versus
$2587 for the average Medicare beneﬁciary). The average mental
health patient ﬁlled over 50 prescriptions for all medical prob-
lems. More than 30% would have entered the donut hole. Schiz-
ophrenia patients would have entered after about 4 months (in
April). Depression patients would fall into the donut hole after
about 6 months, while anxiety patients would enter after about
9 months, on average. Average out-of-pocket pharmacy pay-
ments under the new law would have ranged from $1858 for
anxiety patients to $2407 for schizophrenia patients. CON-
CLUSIONS: Most patients with these psychiatric conditions will
face high out of pocket costs, and will be faced with a donut
hole of no coverage. Implications for adherence to pharma-
cotherapy and overall health should be considered by doctors
and policy makers.
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OBJECTIVES: The research objective is to examine whether
there are racial and ethnic disparities in health expenditures and
health status. Health expenditure and health status are examined
together because theoretically higher spending on health care ser-
vices should lead to better health status. METHODS: The data
were drawn from a nationally representative sample of non-
institutionalized U.S. civilians in the Medical Expenditure Panel
Survey (1996 and 2001). The racial and ethnic disparities were
examined separately by comparing non-Hispanic whites, non-
Hispanic blacks, and Hispanic whites (Hispanic blacks were
excluded due to small sample size). Disparities in self-perceived
health status (poor, fair, good, very good, and excellent) were
compared across racial and ethnic groups using an ordered logis-
tic regression. Disparities in health expenditure were compared
using linear regression (A two-part model was also used to
conﬁrm the ﬁndings). RESULTS: The study sample included
31,258 non-Hispanic whites, 7349 non-Hispanic black, and
11,248 Hispanic whites. There was an overall signiﬁcantly better
self-perceived health status among non-Hispanic whites than
non-Hispanic blacks and Hispanic whites: non-Hispanic blacks
were 79.29% as likely to report a better self-perceived health
status category compared to non-Hispanic whites (P < 0.01);
Hispanic whites were 77.06% as likely to report a better self-
perceived health status category compared to non-Hispanic
whites (P < 0.01). Overall, non-Hispanic blacks and Hispanic
whites spent $690 less (P < 0.01) and $1365 (P < 0.01) less than
non-Hispanic whites every year. The racial disparities in health
expenditures and self-perceived health status were signiﬁcant
after adjusting for confounders; ethnic disparities in health
expenditures were still signiﬁcant but ethnic disparities in health
status were not signiﬁcant. CONCLUSIONS: Compared with
non-Hispanic whites, non-Hispanic blacks have lower health
expenditure and worse self-perceived health status; Hispanic
whites have lower expenditures but similar self-perceived health
status. Further analysis is warranted to examine the causes for
different patterns of racial and ethnic disparities.
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Evidence from US national health surveys suggests that age-
adjusted prevalence of stroke risk factors varies considerably by
race/ethnicity. What is not known is whether resource use among
hospitalized stroke patients, and the associated cost of inpatient
care, differ by race/ethnicity. OBJECTIVE: To assess racial/ethnic
differences in hospital length of stay and cost related to inpatient
treatment of intracerebral hemorrhage (ICH) in US hospitals.
METHODS: The 2002 Health care Cost and Utilization Project
database was used to examine short-stay acute-care hospital dis-
charges among adult ICH patients. This dataset includes all dis-
charges from 995 hospitals in 35 states. Patients were identiﬁed
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based on primary ICD-9-CM discharge diagnosis of ICH
(431.xx). Patient-level information included demographics
(including race/ethnicity: White, Black, Hispanic, Asian), hospi-
tal characteristics, comorbidities, primary payer, admission
source, discharge destination, DRG, length of stay (LOS), and
hospital charges. Costs were estimated by applying hospital-
speciﬁc cost-to-charge ratios to charges. Adjusted LOS and cost
(controlling for age, in-hospital mortality, and other covariates)
by race/ethnicity were estimated using multivariate least-squares
regression. RESULTS: Black, Hispanic, and Asian patients with
a primary diagnosis of ICH at discharge were signiﬁcantly
younger, on average, than White patients (73.5 vs. 61.2, 63.9,
and 67.9 years, respectively; p < 0.01 for all comparisons). Black
and Hispanic patients experienced longer hospital stays (p <
0.01) and incurred higher costs (p < 0.01), on average, than
White patients. Among Black and Hispanic patients, adjusted
length of stay (mean costs) per discharge were approximately 2.3
days ($1400) and 1.7 ($3400) higher, respectively, as compared
to White patients. Asian patients had longer adjusted stays (2.6
additional days, p < 0.01) and higher costs ($830, p < 0.31).
CONCLUSIONS: There are meaningful differences in length of
stay and cost of ICH hospitalizations among patients with dif-
ferent race/ethnicity. Improved acute treatment of stroke in this
high-risk population may help to improve overall outcomes in
these subgroups.
HIGH IMPACT
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OBJECTIVES: To assess the association between
overweight/obesity and employment to population ratio (E/P
Ratio), hourly wage, and annual income in the U.S. METHODS:
Adults (age 18–64) in the 2000–2002 Medical Expenditure 
Panel Survey (MEPS) were classiﬁed as normal weight
(BMI:18.5–24.9), overweight (BMI:25–29.9), and obese (BMI:
>= 30). Underweight (BMI < 18.5) individuals were excluded.
E/P ratio, hourly wage, annual income, and poverty status of the
overweight and obese adults were compared to that of the
normal weight adults, respectively, adjusting for demographic
characteristics using a stratiﬁcation matching method. MEPS
sampling weights were applied to ensure nationally representa-
tive estimates. The analyses were also conducted for population
subgroups deﬁned by gender, race, ethnicity, and physical activ-
ity. RESULTS: The study sample includes 35,989 adults, with
13,744 normal weight, 13,321 overweight, and 8,924 obese. The
E/P ratio was 87.1% for the overweight sample, 1.8% higher (p
< 0.01) than the normal weight sample; and 82.4% for the obese
sample, 1.7% lower (p < 0.01) than the normal weight sample.
The obese sample made $1.63 less per hour (p < 0.01), and
$3338 less annually compared to the normal weight sample (p
< 0.01). Compared to the normal weight sample, obese adults
were more likely to be poor. No signiﬁcant difference of annual
income and poverty level were found between the overweight
and the normal weight sample. Systematic differences between
different population subgroups were found. CONCLUSIONS:
Obese adults are less likely to be employed, have lower annual
incomes and hourly wages, and are more likely to be poor than
normal weight adults.
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OBJECTIVE: To examine the incidence of overactive bladder
(OAB)-related clinical events for elderly patients receiving phar-
macotherapy compared with those receiving non-pharmacologic
management. METHODS: Data were obtained from the Phar-
Metrics Patient-Centric Database on continuously beneﬁt-
eligible patients aged ≥65 years diagnosed with OAB between
January 2002 and December 2003. Patients were categorized
into 2 cohorts: those receiving pharmacotherapy, including long-
acting tolterodine, or immediate- or extended-release oxybutynin
and those receiving non-pharmacologic management. Patients
were matched 1 :1 by the estimated propensity score for OAB
pharmacotherapy using a logistic regression model that included
selected demographic and clinical characteristics. The incidence
of clinical events, including assessment of depression, urinary
tract infections (UTIs), and falls or fractures was evaluated.
Crude event rates were reported, as well as the risk of an event
using Cox proportional hazards models adjusting for important
demographic and clinical characteristics. RESULTS: A total of
1681 matched pairs were identiﬁed. Mean ± SD age was 78 ± 8
years; 60% were women. After matching, differences in baseline
patient characteristics between cohorts were not signiﬁcant. The
incidence of depression (10.2% for pharmacotherapy vs 11.0%
for non-pharmacologic management; p = NS) and fractures
(8.6% vs 10.1%; p = NS) was numerically lower in the drug-
treated cohort, and the incidence of UTI was signiﬁcantly lower
(28.1% vs 36.5%; p < 0.0001). Adjusted rates using Cox pro-
portional hazards models were similar, with no difference in the
risk of depression (hazard ratio [HR] = 0.980; 95% conﬁdence
interval [CI], 0.795–1.208; p = NS) or fractures (HR = 0.863;
95% CI, 0.691–1.079; p = NS) between the cohorts, and the risk
of UTI was 28% lower among pharmacotherapy patients (HR =
0.718; 95% CI, 0.636–0.810; p < 0.0001). CONCLUSIONS:
Pharmacotherapy may impart selected clinical beneﬁts for some
elderly patients with OAB compared with non-pharmacologic
management. Careful consideration should be given to the selec-
tion of treatment approaches in this high-risk population.
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OBJECTIVES: We examined the effects of statin prescription
drug copayments and statin adherence on cardiovascular uti-
lization patterns, medical and prescription drug expenditures
and other outcomes of statin therapy. METHODS: The
2001–2003 MarketScan database was used to study the health
care utilization and expenditure patterns of continuously
enrolled statin users in employer sponsored health plans. We
analyzed the utilization patterns of 93,296 continuing users who
had previously ﬁlled at least one statin prescription in 2000 and
24,128 users who were new to statin therapy in the ﬁrst half of
2001. A two-stage estimation approach consisted of a multi-
variate logit model estimating the relationship between copay-
